This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail his research group's efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality, actionability, and translatability of this information, specifically, the use of accumulation rules to convert high-value […]

Despite drug resistance growing, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development, and how can all of us—doctors, hospitals, and patients, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists will examine the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs.

In this webinar, Olga Genilloud will discuss the role of natural products in current antibiotic discovery. Topics discussed will include: Screening strategies to identify novel antibiotics Current challenges and novel analytical tools New omic approaches supporting antibiotic discovery The presentation will be followed by a Q&A session.   Speaker: Olga Genilloud, Scientific Director, Fundación MEDINA, […]

In this webinar, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial research. This webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research (see here: http://bit.ly/2ZiPt6y). Topics […]

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this webinar, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences, Uppsala University, Sweden), will discuss: Population PK modelling to characterize drug exposure and variability PKPD-modelling […]

Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar […]

Kevin Outterson, CARB-X Executive Director, and Karen Gallant, CARB-X Global R&D Project Director, present details of CARB-X’s four new funding rounds announced April 30, 2019, and answer questions during this webinar. To attend the live webinar, please register by clicking the link below. A recording of the webinar will be available for viewing shortly after […]

Speakers include Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH, member of the CARB-X Joint Oversight Committee. In this presentation, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development […]